Table 3.

Risk Factors for New-Onset Hepatic Decompensation

Factor	Overall (n=318)				Matched (n=224)
	Unadjusted HR (95% CI)	p-value	Multivariable HR (95% CI)	p-value	Unadjusted HR (95% CI)	p-value	Multivariable HR (95% CI)	p-value
Age,/yr	1.01 (0.99–1.03)	0.11	1.01 (0.98–1.03)	0.39	1.00 (0.97–1.03)	0.97	1.00 (0.97–1.04)	0.70
Male (vs female)	0.89 (0.57–1.38)	0.60	0.86 (0.54–1.39)	0.56	0.93 (0.50–1.71)	0.81	0.96 (0.50–1.81)	0.90
Child-Pugh class B/C (vs A)	1.29 (0.72–2.30)	0.38			0.96 (0.44–2.08)	0.92
ECOG 1–4 (vs 0)	1.93 (1.10–3.39)	0.021	1.24 (0.69–2.21)	0.45	1.52 (0.73–3.17)	0.25
mUICC stage
I	1		1		1		1
II	1.10 (0.60–2.02)	0.73	0.94 (0.51–1.73)	0.84	1.34 (0.62–2.90)	0.44	0.91 (0.41–2.02)	0.83
III	2.05 (1.12–3.75)	0.020	1.29 (0.69–2.41)	0.41	1.95 (0.89–4.30)	0.095	0.99 (0.43–2.27)	0.98
IV	2.90 (1.36–6.15)	0.005	1.90 (0.85–4.22)	0.11	4.29 (1.65–11.1)	0.003	2.07 (0.75–5.76)	0.16
Baseline HBV DNA,/log IU/mL	1.08 (0.95–1.23)	0.22			1.04 (0.97–1.11)	0.21
HBV DNA ≥20,000 IU/mL (yes vs no)	1.69 (0.98–2.91)	0.056	1.84 (1.05–3.21)	0.031	1.67 (0.90–3.08)	0.10	1.65 (0.87–3.11)	0.12
LAM (vs ETV)	1.90 (1.31–2.76)	0.001	1.67 (1.12–2.48)	0.010	1.39 (0.89–2.16)	0.14	1.45 (0.92–2.29)	0.10
Curative treatment (vs palliative)	0.21 (0.14–0.32)	<0.001	0.27 (0.17–0.41)	<0.001	0.21 (0.13–0.35)	<0.001	0.24 (0.14–0.40)	<0.001

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group performance status; mUICC, modified Union for International Cancer Control; HBV, hepatitis B virus; LAM, lamivudine; ETV, entecavir.